114 related articles for article (PubMed ID: 27327536)
21. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
22. Relationship between Variation of Pre-ablation Stimulated Thyroglobulin and Distant Metastasis in Patients with Differentiated Thyroid Cancer.
Zhao T; Liang J; Li TJ; Li CX; Hui C; Yang K; Li F; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Jun; 37(3):315-9. PubMed ID: 26149144
[TBL] [Abstract][Full Text] [Related]
23. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients.
Crocetti U; Durante C; Attard M; Maniglia A; Tumino S; Bruno R; Bonfitto N; Dicembrino F; Varraso A; Meringolo D; Filetti S; Trischitta V; Torlontano M
Thyroid; 2008 Oct; 18(10):1049-53. PubMed ID: 18816184
[TBL] [Abstract][Full Text] [Related]
25. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
[TBL] [Abstract][Full Text] [Related]
26. Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later.
Melo M; Costa G; Ribeiro C; Carrilho F; Martins MJ; da Rocha AG; Sobrinho-Simões M; Carvalheiro M; Soares P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4364-72. PubMed ID: 24037891
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
[TBL] [Abstract][Full Text] [Related]
28. Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
Kloos RT
J Clin Endocrinol Metab; 2010 Dec; 95(12):5241-8. PubMed ID: 20843945
[TBL] [Abstract][Full Text] [Related]
29. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.
Webb RC; Howard RS; Stojadinovic A; Gaitonde DY; Wallace MK; Ahmed J; Burch HB
J Clin Endocrinol Metab; 2012 Aug; 97(8):2754-63. PubMed ID: 22639291
[TBL] [Abstract][Full Text] [Related]
30. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
[TBL] [Abstract][Full Text] [Related]
31. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma.
González C; Aulinas A; Colom C; Tundidor D; Mendoza L; Corcoy R; Mato E; Alcántara V; Urgell Rull E; de Leiva A
Clin Endocrinol (Oxf); 2014 Feb; 80(2):301-6. PubMed ID: 23826916
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
33. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
Schlumberger M
Clin Endocrinol (Oxf); 2005 Feb; 62(2):119-20. PubMed ID: 15670184
[No Abstract] [Full Text] [Related]
34. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment.
Han JM; Kim WB; Yim JH; Kim WG; Kim TY; Ryu JS; Gong G; Sung TY; Yoon JH; Hong SJ; Kim EY; Shong YK
Thyroid; 2012 Aug; 22(8):784-90. PubMed ID: 22780573
[TBL] [Abstract][Full Text] [Related]
35. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
[TBL] [Abstract][Full Text] [Related]
36. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
37. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
38. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
39. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
[TBL] [Abstract][Full Text] [Related]
40. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
